DCPH insider filings
Deciphera Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-24. Screen DCPH transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for DCPH between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Deciphera Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-04-24 | 4 | Brightstar Associates LLC — 10% owner | Option exercise/expiry (X): 48,136 @ $0.01 · Option exercise/expiry (X): 48,136 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Dhanak Dashyant — EVP & Chief Scientific Officer | Grant/award (A): 17,275 @ $0 · Grant/award (A): 69,100 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Martin Daniel C. — Chief Commercial Officer | Grant/award (A): 9,725 @ $0 · Sale (S): 2,267 @ $15.62 · Grant/award (A): 38,900 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Pitman Jama — SVP, Chief Development Officer | Grant/award (A): 9,725 @ $0 · Grant/award (A): 10,000 @ $0 · Sale (S): 2,267 @ $15.62 · Grant/award (A): 38,900 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Hoerter Steven L. — President and CEO, Director | Grant/award (A): 298,100 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Grant/award (A): 17,275 @ $0 · Sale (S): 3,010 @ $15.62 · Grant/award (A): 69,100 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Grant/award (A): 17,275 @ $0 · Sale (S): 2,615 @ $15.62 · Grant/award (A): 69,100 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Brightstar Associates LLC — 10% owner | Option exercise/expiry (X): 914,001 @ $0.01 · Option exercise/expiry (X): 914,001 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Walsh Dennis Leo — Director | Grant/award (A): 4,727 (derivative) @ $10.58 | EDGAR |
| 2024-01-18 | 4 | Pitman Jama — SVP, Chief Development Officer | Sale (S): 1,624 @ $14.47 | EDGAR |
| 2024-01-18 | 4 | Friedman Franklin Stuart — Director | Grant/award (A): 4,727 (derivative) @ $10.58 | EDGAR |
| 2024-01-18 | 4 | Martin Daniel C. — Chief Commercial Officer | Sale (S): 1,624 @ $14.47 | EDGAR |
| 2024-01-18 | 4 | Squarer Ron — Director | Grant/award (A): 4,727 (derivative) @ $10.58 | EDGAR |
| 2024-01-18 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Sale (S): 2,435 @ $14.47 | EDGAR |
| 2024-01-18 | 4 | Allen Patricia L — Director | Grant/award (A): 4,727 (derivative) @ $10.58 | EDGAR |
| 2024-01-18 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Sale (S): 2,435 @ $14.47 | EDGAR |
| 2023-12-14 | 4 | Pitman Jama — See Remarks | Grant/award (A): 5,576 · Sale (S): 1,662 @ $15.37 | EDGAR |
| 2023-12-14 | 4 | Martin Daniel C. — Chief Commercial Officer | Grant/award (A): 5,576 · Sale (S): 1,727 @ $15.37 | EDGAR |
| 2023-12-14 | 4 | Hoerter Steven L. — President and CEO, Director | Grant/award (A): 62,500 · Sale (S): 30,664 @ $15.37 | EDGAR |
| 2023-12-14 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Grant/award (A): 8,244 · Sale (S): 2,792 @ $15.37 | EDGAR |
| 2023-12-14 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Grant/award (A): 8,244 · Sale (S): 2,792 @ $15.37 | EDGAR |
| 2023-12-01 | 4 | Martin Daniel C. — Chief Commercial Officer | Sale (S): 17,801 @ $12.57 | EDGAR |
| 2023-10-31 | 4 | Pitman Jama — See Remarks | Grant/award (A): 5,576 · Sale (S): 1,407 @ $12.02 | EDGAR |
| 2023-10-31 | 4 | Martin Daniel C. — Chief Commercial Officer | Grant/award (A): 5,576 · Sale (S): 1,407 @ $12.02 | EDGAR |
| 2023-10-31 | 4 | Hoerter Steven L. — President and CEO, Director | Grant/award (A): 62,500 · Sale (S): 21,573 @ $12.02 | EDGAR |
| 2023-10-31 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Grant/award (A): 8,244 · Sale (S): 2,316 @ $12.02 | EDGAR |
| 2023-10-31 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Grant/award (A): 8,244 · Sale (S): 2,360 @ $12.02 | EDGAR |
| 2023-10-04 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Sale (S): 2,942 @ $12.68 | EDGAR |
| 2023-09-19 | 4 | Dhanak Dashyant — EVP & Chief Scientific Officer | Grant/award (A): 65,900 @ $0 · Grant/award (A): 75,000 @ $0 · Grant/award (A): 65,900 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Bristol James Arthur — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Walsh Dennis Leo — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Martin John Richard — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Benz Edward J. JR — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Friedman Franklin Stuart — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Kelley Susan L. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Squarer Ron — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Allen Patricia L — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Pitman Jama — See Remarks | Sale (S): 1,238 @ $14.40 | EDGAR |
| 2023-06-21 | 4 | Martin Daniel C. — Chief Commercial Officer | Sale (S): 1,238 @ $14.40 | EDGAR |
| 2023-06-21 | 4 | Flynn Daniel Lee — Chief Scientific Officer | Sale (S): 1,655 @ $14.40 | EDGAR |
| 2023-06-21 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Sale (S): 1,655 @ $14.40 | EDGAR |
| 2023-06-21 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Sale (S): 1,655 @ $14.40 | EDGAR |
| 2023-06-12 | 4 | Friedman Franklin Stuart — Director | Purchase (P): 10,000 @ $13.88 | EDGAR |
| 2023-05-12 | 4 | Walsh Dennis Leo — Director | Purchase (P): 11,000 @ $13.86 | EDGAR |
| 2023-03-23 | 4 | Hoerter Steven L. — President and CEO, Director | Sale (S): 7,500 @ $15.57 | EDGAR |
| 2023-03-01 | 4 | Brightstar Associates LLC — 10% owner | Option exercise/expiry (X): 2,427,693 @ $0.01 · Option exercise/expiry (X): 2,427,693 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Martin Daniel C. — Chief Commercial Officer | Grant/award (A): 11,151 @ $0 · Sale (S): 1,159 @ $15.10 · Grant/award (A): 44,600 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Flynn Daniel Lee — Chief Scientific Officer | Grant/award (A): 16,488 @ $0 · Sale (S): 1,370 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Grant/award (A): 16,488 @ $0 · Sale (S): 1,370 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Sherman Matthew L — EVP & Chief Medical Officer | Grant/award (A): 16,488 @ $0 · Sale (S): 971 @ $15.10 · Grant/award (A): 65,900 (derivative) @ $0 | EDGAR |
Recent 8-K events — Deciphera Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-06-11 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-05-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DCPH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs